Cellphire Therapeutics ceases enrolment in trial of CLPH-511 following IDMC feedback

Cellphire Therapeutics has halted enrolling subjects in its CRYPTICS trial of CLPH-511, following positive feedback from an independent data monitoring committee. The trial, assessing CLPH-511—a cryopreserved platelet product—aims to treat uncontrolled haemorrhage in patients undergoing cardiopulmonary bypass surgery.

The pre-planned interim analysis of safety and efficacy data from over 150 subjects showed that CLPH-511 achieved its primary efficacy endpoint: 24-hour chest tube drainage, demonstrating non-inferiority to the standard room-temperature control platelet product, with a statistical significance (p-value < 0.00965).

Cellphire views the results as a significant step in developing long-shelf-life platelet alternatives to improve access to essential care worldwide. With enrollment now complete, the company expects to collect final trial data by Q2 2025 and plans to provide further updates as it continues developing cryopreserved platelet products.

The trial is supported by the US Army Medical Research and Development Command.

26-04-2025